Kythera Biopharmaceuticals Announces Positive Results from Phase IIb Study with ATX-101 Demonstrating Reduction of Submental Fat

LOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”) today announced that it has successfully completed a third Phase II clinical study with ATX-101, a first-in-class adipolytic agent that is under investigation for the reduction of submental (‘under-the-chin’) fat. The Phase IIb, randomized, double-blind, placebo-controlled, dose-ranging study showed ATX-101 was well tolerated and demonstrated statistically significant efficacy as compared with placebo. The study enrolled a total of 129 subjects and was conducted across 10 dermatology and plastic surgery centers in the United States. Multiple clinician and patient endpoints were assessed, as well as MRI to objectively quantify fat reduction. The study tested two drug-dosing regimens (1 and 2 mg/cm2).